<DOC>
	<DOCNO>NCT01190657</DOCNO>
	<brief_summary>This self-controlled , open , multiple-center clinical trial .</brief_summary>
	<brief_title>Efficacy Safety Teprenone Patients With Acute Gastritis , Acute Gastric Lesion Chronic Gastritis With Acute Exacerbation Gastric Ulcer</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Gastritis , Atrophic</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Geranylgeranylacetone</mesh_term>
	<criteria>Inclusion criterion 1 . Age 18 year old , men woman 2 . Erosive lesion flat lesion thin white coat acute gastritis , acute stage chronic gastritis three lesion ( include three lesion ) endoscopy prior study 3 day diagnose clinical symptom sign ; 3 . Signed informed consent form . Exclusion criteria 1 . Patients without inclusion criterion 2 . Patients significant cardiovascular , pulmonary , hepatic , renal hemopoietic system primary disease 3 . Patients digestive disease . 4 . Patients operation stomach duodenum . 5 . Patients administer nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroids 6 . Patients severity trauma , surgery , infection shock . 7 . Patients kind tumor 8 . Women either pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Teprenone</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>acute gastric lesion</keyword>
	<keyword>chronic gastritis</keyword>
</DOC>